CSF-1R Antibody Specificity vs Off-Target Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and bone degradation associated with CSF-1 activity are limited in efficacy, as existing inhibitors often have non-specific effects and do not fully address the role of CSF-1 in tumor progression and osteoclast activity.
Innovation Solution
Development of a recombinant antibody specifically binding to the CSF-1R, characterized by specific variable regions, which selectively inhibits CSF-1R activity without competing with IL-34 ligand binding, thereby targeting CSF-1R-expressing cells, including cancer cells and osteoclasts, to reduce tumor growth and bone resorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CSF-1 inhibitors are used, then CSF-1 activity is suppressed, but the inhibitors have non-specific effects and do not fully address tumor progression and osteoclast activity
Solution Approach 1:
The patent applies local quality by designing an antibody that specifically targets the CSF-1R receptor with high precision, rather than using non-specific inhibitors. The antibody's variable regions are engineered to recognize a specific epitope on the CSF-1R, providing localized inhibition at the receptor level while avoiding off-target effects. This resolves the contradiction by achieving specific suppression of CSF-1R-mediated pathways without the non-specific harmful effects of broader inhibitors.
Solution Approach 2:
The patent uses an antibody as an intermediary substance to mediate the inhibition of CSF-1 activity. Instead of directly suppressing CSF-1 ligand binding, the antibody binds to the CSF-1R receptor, blocking the ligand-receptor interaction. This intermediary approach allows for more precise control over the inhibition mechanism, addressing tumor progression and osteoclast activity specifically without the non-specific effects of direct CSF-1 inhibition.
2Reliability
If CSF-1R is inhibited to treat cancer, then tumor growth is reduced, but osteoclast activity and bone resorption are also affected
Solution Approach 1:
The patent applies universality by designing a CSF-1R targeting antibody that simultaneously addresses multiple functions: inhibiting tumor growth, suppressing osteoclast differentiation, and potentially protecting bone health. The same mechanism blocks both malignant and benign CSF-1R-expressing cells, creating a multi-functional therapeutic effect that resolves the contradiction between cancer treatment efficacy and bone health preservation.
Solution Approach 2:
The patent converts the harmful effect of CSF-1R inhibition on bone health into a beneficial outcome by targeting the same receptor that drives both tumor progression and osteoclast activity. By blocking CSF-1R, the therapy simultaneously reduces cancer growth and prevents bone resorption, turning what would normally be a harmful side effect into a therapeutic benefit for bone preservation.
3Reliability
If a recombinant antibody is developed to specifically bind CSF-1R, then selective inhibition is achieved, but the complexity of antibody characterization and production increases
Solution Approach 1:
The patent applies copying by using recombinant DNA technology to produce the antibody through genetic engineering rather than traditional immunization methods. The antibody genes are synthesized and expressed in host cells, creating identical copies of the therapeutic antibody. This approach simplifies production scalability and ensures consistency in selectivity while reducing the complexity of traditional animal-based antibody generation and characterization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody effectively inhibits CSF-1R-mediated proliferation and osteoclast differentiation, demonstrating potential in treating cancer and bone-related disorders by selectively targeting CSF-1R, thereby reducing tumor progression and bone loss.
Implementation Method 1
an isolated, recombinant or purified antibody that specifically binds to the CSF-1R
Implementation Method 2
said antibody comprises: (i) (a) first variable region consisting in SEQ ID NO:42, and (b) a second variable region consisting in SEQ ID NO:44; or (ii) (a) first variable region consisting in SEQ ID NO:43, and (b) a second variable region consisting in SEQ ID NO:45
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides antibodies specific for the CSF-1 R, compositions comprising said antibodies and methods of treatment using such compositions.